Skip to main content
Erschienen in: Tumor Biology 5/2013

01.10.2013 | Research Article

The expression of glutamine-metabolism-related proteins in breast phyllodes tumors

verfasst von: Sewha Kim, Woo Hee Jung, Ja Seung Koo

Erschienen in: Tumor Biology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the expression of glutamine-metabolism-related proteins according to the histologic grade of phyllodes tumors (PTs) and to assess its clinical implication. We generated tissue microarrays of 224 PTs and performed immunohistochemical staining and western blot analysis of glutamine-metabolism-related molecules, including GLS1, GDH, and ASCT2. The associations between immunohistochemical results and clinicopathologic parameters were evaluated. The expression of GLS1 (p < 0.001), GDH (p < 0.001), and ASCT2 (p = 0.005) in stromal components significantly increased with worsening PT histological grade. GDH expression in epithelial components significantly increased in high-grade PT (p = 0.026). In western blot, stromal expression of GLS1, GDH, and ASCT2 increased as histologic grade increased. By univariate analysis, stromal GLS1 expression (p = 0.022) and stromal GDH expression (p = 0.009) were independent predictors of shorter DFS. Stromal GLS1 expression (p < 0.001) and stromal GDH expression (p < 0.001) were independent predictors of shorter OS. This study demonstrated that the stromal expression of the glutamine-metabolism-related proteins GLS1, GDH, ASCT2 increases with worsening histological PT grade.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
3.
Zurück zum Zitat Collins CL, Wasa M, Souba WW, Abcouwer SF. Regulation of glutamine synthetase in human breast carcinoma cells and experimental tumors. Surgery. 1997;122:451–63. discussion 63–4.CrossRefPubMed Collins CL, Wasa M, Souba WW, Abcouwer SF. Regulation of glutamine synthetase in human breast carcinoma cells and experimental tumors. Surgery. 1997;122:451–63. discussion 63–4.CrossRefPubMed
4.
Zurück zum Zitat Friday E, Oliver 3rd R, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: relationship to mitochondrial membrane potential. J Cell Physiol. 2011;226:511–9.CrossRefPubMed Friday E, Oliver 3rd R, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: relationship to mitochondrial membrane potential. J Cell Physiol. 2011;226:511–9.CrossRefPubMed
5.
Zurück zum Zitat McGivan JD, Bungard CI. The transport of glutamine into mammalian cells. Front Biosci. 2007;12:874–82.CrossRefPubMed McGivan JD, Bungard CI. The transport of glutamine into mammalian cells. Front Biosci. 2007;12:874–82.CrossRefPubMed
6.
Zurück zum Zitat Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995;15:133–59.CrossRefPubMed Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995;15:133–59.CrossRefPubMed
7.
Zurück zum Zitat Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle. 2010;9:3884–6.CrossRefPubMed Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle. 2010;9:3884–6.CrossRefPubMed
8.
Zurück zum Zitat Tavassoli FA, Devilee P, International Agency for Research on Cancer (IAPS), World Health Organization. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IAPS; 2003. Tavassoli FA, Devilee P, International Agency for Research on Cancer (IAPS), World Health Organization. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IAPS; 2003.
9.
Zurück zum Zitat Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, et al. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol. 2001;116:129–34.CrossRefPubMed Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, et al. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol. 2001;116:129–34.CrossRefPubMed
10.
Zurück zum Zitat Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979–85.CrossRefPubMed Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979–85.CrossRefPubMed
11.
Zurück zum Zitat Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res. 1998;4:115–20.CrossRefPubMed Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res. 1998;4:115–20.CrossRefPubMed
12.
Zurück zum Zitat Stackhouse BL, Williams H, Berry P, Russell G, Thompson P, Winter JL, et al. Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat. 2005;93:247–53.CrossRefPubMed Stackhouse BL, Williams H, Berry P, Russell G, Thompson P, Winter JL, et al. Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat. 2005;93:247–53.CrossRefPubMed
13.
Zurück zum Zitat Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895–8.PubMed Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895–8.PubMed
14.
Zurück zum Zitat Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69:7986–93.PubMedCentralCrossRefPubMed Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69:7986–93.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res. 1993;53:4071–4.PubMed Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res. 1993;53:4071–4.PubMed
16.
Zurück zum Zitat Sawyer EJ, Hanby AM, Ellis P, Lakhani SR, Ellis IO, Boyle S, et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol. 2000;156:1093–8.PubMedCentralCrossRefPubMed Sawyer EJ, Hanby AM, Ellis P, Lakhani SR, Ellis IO, Boyle S, et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol. 2000;156:1093–8.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–5.PubMedCentralCrossRefPubMed Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–5.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Sawyer EJ, Poulsom R, Hunt FT, Jeffery R, Elia G, Ellis IO, et al. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol. 2003;200:59–64.CrossRefPubMed Sawyer EJ, Poulsom R, Hunt FT, Jeffery R, Elia G, Ellis IO, et al. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol. 2003;200:59–64.CrossRefPubMed
19.
Zurück zum Zitat Kwon JE, Jung WH, Koo JS. The expression of metabolism-related proteins in phyllodes tumors. Tumour Biol. 2013;34:115–24.CrossRefPubMed Kwon JE, Jung WH, Koo JS. The expression of metabolism-related proteins in phyllodes tumors. Tumour Biol. 2013;34:115–24.CrossRefPubMed
20.
Zurück zum Zitat Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943–9.CrossRefPubMed Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943–9.CrossRefPubMed
21.
22.
Zurück zum Zitat Morris DI, Robbins JD, Ruoho AE, Sutkowski EM, Seamon KB. Forskolin photoaffinity labels with specificity for adenylyl cyclase and the glucose transporter. J Biol Chem. 1991;266:13377–84.PubMed Morris DI, Robbins JD, Ruoho AE, Sutkowski EM, Seamon KB. Forskolin photoaffinity labels with specificity for adenylyl cyclase and the glucose transporter. J Biol Chem. 1991;266:13377–84.PubMed
23.
Zurück zum Zitat Niculescu-Duvaz I. Glufosfamide (Baxter Oncology). Curr Opin Investig Drugs. 2002;3:1527–32.PubMed Niculescu-Duvaz I. Glufosfamide (Baxter Oncology). Curr Opin Investig Drugs. 2002;3:1527–32.PubMed
24.
Zurück zum Zitat Subbarayan PR, Wang PG, Lampidis TJ, Ardalan B, Braunschweiger P. Differential expression of Glut 1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types. J Chemother. 2008;20:106–11.CrossRefPubMed Subbarayan PR, Wang PG, Lampidis TJ, Ardalan B, Braunschweiger P. Differential expression of Glut 1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types. J Chemother. 2008;20:106–11.CrossRefPubMed
Metadaten
Titel
The expression of glutamine-metabolism-related proteins in breast phyllodes tumors
verfasst von
Sewha Kim
Woo Hee Jung
Ja Seung Koo
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0819-7

Weitere Artikel der Ausgabe 5/2013

Tumor Biology 5/2013 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.